Skip to content

Stress Hydrocortisone in Pediatric Septic Shock

Septic Shock

SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic shock.

It is hypothesized that adjunctive hydrocortisone will significantly reduce the incidence of new and progressive organ dysfunction (primary outcome) and proportion of children with poor outcomes, defined as death or severely impaired health-related quality of life (HRQL) (secondary outcome), as assessed at 28 days following study enrollment (randomization).

null

Conditions de participation

  • Sexe:

    ALL
  • Âges admissibles:

    1 to 17

Critères de participation

Inclusion Criteria:

A child receiving treatment in a pediatric intensive care unit is eligible for recruitment into SHIPSS if she/he meets all of the following inclusion criteria:

1. Age is at least 1 month (with corrected gestational age ≥42 weeks), but less than 17 years and 8 months of age
2. A documented focus of infection or a strong suspicion of infection at PICU admission, or for patients who develop septic shock during PICU stay, at the onset of the septic shock event
3. Surveillance cultures (e.g. blood, urine, cerebral spinal fluid, wound) and/or other microbial diagnostic tests have been obtained
4. One or more antimicrobials have been prescribed
5. Core temperature \>38.5 C or \<36.0 C or leukocytosis or leukopenia (as defined by the local laboratory) or a left-shifted leukocyte differential (\>10% immature granulocyte forms) or a neutrophil count of \<0.5 x 109 cells per litre documented at least once within the 24 hours preceding screening
6. Treatment with a continuous infusion of vasoactive-inotropic agent(s) to maintain mean or systolic arterial blood pressure above the age-appropriate target set by the treating clinician
7. Administration of two or more vasoactive-inotropic agents at any dose or epinephrine or norepinephrine infusion(s) alone at greater than or equal to 0.10 mcg/kg/min for \>1 hour.

Exclusion Criteria:

A child receiving treatment in a pediatric intensive care unit for sepsis is ineligible for enrollment into SHIPSS if she/he meets any of the following exclusion criteria:

1. All inclusion criteria have been present for \> 12 hours
2. Attending physician expects to prescribe systemic corticosteroids for an indication other than septic shock
3. Patient has received any doses of systemic corticosteroids during treatment for sepsis
4. Enrolled concurrently in a competing interventional clinical trial (formal assessment to be conducted by SHIPSS Core Committee for each potential competing trial)
5. Etomidate or ketoconazole treatment within past 48 hours
6. Patient in whom steroids are contraindicated at time of screening (e.g. treatment for systemic fungal infection, cerebral malaria, strongyloides)
7. Known or suspected hypothalamic, pituitary or adrenal disease (including patient has received acute or chronic corticosteroid administration and the physician intends to provide corticosteroid for suspected adrenal suppression)
8. Attending physician, PICU care team, or legally recognized guardians not committed to full treatment and resuscitation at the time of screening
9. Patient documented to be pregnant
10. Previous enrollment in the SHIPSS study
11. Patient admitted directly to the PICU with a thermal burn who has been in the PICU for \<72 hours prior to meeting SHIPSS inclusion criteria.
12. (U.S. sites only) Patient in the custody of US protective services
13. Patient being evaluated for brain death
14. Vasoactive-inotropic agents prescribed solely for an indication other than septic shock
15. Confirmed dengue fever

Lieu de l'étude

McMaster Children's Hospital
McMaster Children's Hospital
Hamilton, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Karen Choong, MD

Montreal Children's Hospital
Montreal Children's Hospital
Montréal, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Patricia Fontela, MD

IWK Health Centre
IWK Health Centre
Halifax, Nova Scotia
Canada

Contactez l'équipe d'étude

Primary Contact

Neeraj Verma, MD

Centre hospitalier universitaire Sainte-Justine
Centre hospitalier universitaire Sainte-Justine
Montréal, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Marisa Tucci, MD

Alberta Children's Hospital
Alberta Children's Hospital
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Primary Contact

Megan Mahoney, MD

London Health Sciences Centre
London Health Sciences Centre
London, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Douglas Fraser, MD

Centre hospitalier de l'Université Laval
Centre hospitalier de l'Université Laval
Québec, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Matthew Weiss, MD

BC Children's Hospital
BC Children's Hospital
Vancouver, British Columbia
Canada

Contactez l'équipe d'étude

Children's Hospital of Eastern Ontario
Children's Hospital of Eastern Ontario
Ottawa, Ontario
Canada

Contactez l'équipe d'étude

Backup Contact

James D McNally, MD, PhD

Primary Contact

Kusum Menon, MD

[email protected]
613-737-7600
Backup Contact

Katie O'Hearn, MSc

[email protected]
613-737-7600
Royal University Hospital
Royal University Hospital
Saskatoon, Saskatchewan
Canada

Contactez l'équipe d'étude

Étude parrainée par
Seattle Children's Hospital
Participants recherchés
Plus d'informations
ID de l'étude: NCT03401398